My watch list  

7 Current news of Indivumed


You can refine your search further. Select from the filter options on the left to narrow down your results.

Evotec and Indivumed achieve milestone in joint strategic drug discovery collaboration


Evotec SE and Indivumed GmbH announced that the first milestone has been successfully achieved in their joint collaboration to identify new therapeutic targets for the treatment of colorectal cancer. Under the terms of the collaboration agreement, Evotec received full access to the colorectal ...


Evotec and Indivumed announce drug discovery collaboration on precision medicine for colorectal cancer


Evotec SE and Indivumed GmbH announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer (“CRC”). The collaboration, which runs for an initial term of two years, will combine Evotec’s proprietary ...


apceth and Indivumed to Develop Biomarker Platform for Targeted Cellular Therapies


apceth GmbH & Co. KG and Indivumed GmbH have entered into a partnership for the development of a predominantly tissue-based biomarker strategy for the treatment of solid cancers with cellular and / or gene therapeutics. The goal is to predict the response of a targeted cellular / gene therapy in ...


Indivumed appoints Dr. Helge Bastian as Managing Director and Chief Commercial Officer


Indivumed announced that Helge Bastian, Ph.D, will join Indivumed as Managing Director and Chief Commercial Officer on September 12, 2011. Dr. Bastian has over 19 years of international leadership experience in corporations serving the molecular biology, life science research, diagnostics, ...


Indivumed to study the integrity of biospecimen sampling procedures for the U.S. National Cancer Institute

Analysis of biopsy sampling procedures a prerequisite for the development of future individualized cancer therapies


Indivumed GmbH has been awarded a subcontract by SAIC-Frederick, Inc., under its prime contract with the U.S. National Cancer Institute (NCI) to assess the impact of sampling procedures on the integrity of cancer biospecimens and key data derived from them. The NCI’s Office of Biorepositories and ...


Inostics acquires from Johns Hopkins University an exclusive license for detection of PIK3CA

Subsidiary of Indivumed aims to develop DNA-based blood tests for individualizing cancer therapy


Inostics GmbH announced it has obtained a world-wide exclusive license for detection of PIK3CA mutations from Johns Hopkins University (Baltimore, MD). The license grants Inostics, a subsidiary of Indivumed, the exclusive right to use digital PCR techniques and other technologies such as ...


Indivumed appoints Harald Eistetter as Chief Business Officer and Managing Director


Indivumed GmbH announced the appointment of Harald R Eistetter, PhD, as Managing Director and to the newly created position of Chief Business Officer. Dr Eistetter, who has more than two decades of leadership experience in the pharmaceutical and biotech industry, will be responsible in ...


Page 1 From 1
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE